The stock of TC BioPharm (Holdings) plc ADR (TCBP) has seen a -65.32% decrease in the past week, with a -77.10% drop in the past month, and a -92.00% decrease in the past quarter. The volatility ratio for the week is 16.73%, and the volatility levels for the past 30 days are at 15.47% for TCBP. The simple moving average for the last 20 days is -66.56% for TCBP stock, with a simple moving average of -98.96% for the last 200 days.
Is It Worth Investing in TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) Right Now?
The 36-month beta value for TCBP is also noteworthy at 0.01. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of TCBP on March 21, 2025 was 275.24K shares.
TCBP) stock’s latest price update
The stock price of TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) has plunged by -61.04 when compared to previous closing price of 1.54, but the company has seen a -65.32% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-21 that EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with Rule 5550(a)(2) of Nasdaq’s Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share.
TCBP Trading at -85.41% from the 50-Day Moving Average
After a stumble in the market that brought TCBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.89% of loss for the given period.
Volatility was left at 15.47%, however, over the last 30 days, the volatility rate increased by 16.73%, as shares sank -75.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -92.49% lower at present.
During the last 5 trading sessions, TCBP fell by -63.87%, which changed the moving average for the period of 200-days by -99.64% in comparison to the 20-day moving average, which settled at $1.7958. In addition, TC BioPharm (Holdings) plc ADR saw -94.19% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TCBP
The total capital return value is set at -3.6.
Based on TC BioPharm (Holdings) plc ADR (TCBP), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -5.52.
Currently, EBITDA for the company is -13.61 million with net debt to EBITDA at -0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.79.
Conclusion
In summary, TC BioPharm (Holdings) plc ADR (TCBP) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
